Rheumnow Podcast
RheumNow Day 4 Recap ACR Convergence 2024 Highlights
Nov 20, 2024
Joining the discussion are David Liu, a rheumatologist from Melbourne, and Akhil Sood, a fellow at Stanford with expertise in lupus treatment. They dive into groundbreaking studies from the ACR Annual Meeting, spotlighting promising results for Dapirulizumab in lupus care. The conversation shifts to new therapies and the clinical implications for lupus and advancements in AI for diagnosing inflammatory conditions. They also address the risks of steroid use in rheumatic diseases and the emerging management challenges faced by patients.
28:40
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Recent advancements in lupus treatment, particularly Dapirulizumab, show promise in improving responses and steroid tapering for patients.
- The significant indirect costs of lupus, especially for women, highlight the necessity of addressing broader social and economic impacts of the disease.
Deep dives
Advancements in Lupus Treatments
Recent advancements in lupus treatments include the introduction of Dapirulizumab, which is showing promising results in phase two and phase three trials for moderate to severe lupus. These trials indicate better steroid tapering and response rates compared to standard therapies, highlighting the need for new options in managing this complex disease. The discussions also revolved around the significance of biomarkers, which are crucial given the heterogeneous nature of lupus, and how upcoming therapies like CAR-T might provide alternative treatment avenues. Overall, the excitement stems from the potential improvement in patient response and the possibility of better management strategies with these new treatments.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
